



OPEN ACCESS

APPROVED BY

Angelo A. Izzo,
University of Naples Federico II, Italy

*CORRESPONDENCE

Frontiers Editorial Office,
✉ research.integrity@frontiersin.org

RECEIVED 30 August 2023

ACCEPTED 30 August 2023

PUBLISHED 06 September 2023

CITATION

Frontiers Editorial Office (2023),
Retraction: MiR-519b-3p inhibits the
proliferation and invasion in colorectal
cancer via modulating the uMtCK/Wnt
signaling pathway.
Front. Pharmacol. 14:1285746.
doi: 10.3389/fphar.2023.1285746

COPYRIGHT

© 2023 Frontiers Editorial Office. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Retraction: MiR-519b-3p inhibits the proliferation and invasion in colorectal cancer via modulating the uMtCK/Wnt signaling pathway

Frontiers Editorial Office*

A Retraction of the Original Research Article

[MiR-519b-3p inhibits the proliferation and invasion in colorectal cancer via modulating the uMtCK/Wnt signaling pathway](https://doi.org/10.3389/fphar.2019.00741)

by Zhang Y, Sun M, Chen Y and Li B (2019). *Front. Pharmacol.* 10:741. doi: [10.3389/fphar.2019.00741](https://doi.org/10.3389/fphar.2019.00741)

The journal retracts the 02 July 2019 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide the raw data or a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. Given the concerns about the validity of the data, and the lack of raw data, the editors no longer have confidence in the findings presented in the article.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agree with this retraction.